Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose version of its diabetes drug liraglutide that can be used to treat obesity. The Danish ...
Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.
Refer to the Saxenda medication guide for full details. Reduces A1C levels by 1.9% to 2.2% over 40 weeks. Participants also lost 12 to 15 pounds in clinical trials, though it’s not a weight loss ...